HPV+ HNSCC: adding motolimod to EXTREME boosts survival

  • Ferris RL & al.
  • JAMA Oncol
  • 21 Jun 2018

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adding motolimod to the EXTREME chemotherapy regimen (carboplatin/cisplatin, fluorouracil, and cetuximab) is associated with improved survival of patients with head and neck squamous cell carcinoma (HNSCC) with HPV-positive status or injection site reactions.

Why this matters

  • Treatment with motolimod, a toll-like receptor 8 (TLR8) agonist, may stimulate innate and adaptive immunity and benefit certain patient subsets.

Key results

  • In the overall intent-to-treat population, adding motolimod was associated with similar median PFS (6.1 vs 5.9 months; HR, 0.99; P=.47) and OS (13.5 vs 11.3 months; HR, 0.95; P=.40) compared with placebo.
  • In HPV-positive patients, adding motolimod was associated with significantly improved PFS (7.8 vs 5.9 months; HR, 0.58; P=.046) and OS (15.2 vs 12.6 months; HR, 0.41; P=.03) compared with placebo.
  • In patients with injection site reactions, adding motolimod was associated with significantly improved OS (18.7 vs 12.6 months; HR, 0.56; P=.02) compared with placebo.

Study design

  • 195 patients with HNSCC receiving the EXTREME chemotherapy regimen (100 with added motolimod and 95 with added placebo) were analyzed for survival outcomes.
  • Funding: VentiRx Pharmaceuticals.

Limitations

  • Retrospective analysis of HPV-positive patients.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit